Disease · MONDO_0011719
Comparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 29
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Avapritinib vs Regorafinib: deaths from any cause | 89 of 239 | 87 of 234 | 473 | NCT03465722 | Trial comparisons |
| Avapritinib vs Regorafinib: serious adverse events | 106 of 239 | 91 of 234 | 473 | NCT03465722 | Trial comparisons |
| Ripretinib vs Sunitinib: deaths from any cause | 90 of 223 | 95 of 221 | 444 | NCT03673501 | Trial comparisons |
| Ripretinib vs Sunitinib: serious adverse events | 64 of 223 | 61 of 221 | 444 | NCT03673501 | Trial comparisons |
| Sunitinib Double-Blind Treatment vs Placebo Double-Blind Treatment: Confirmed Objective Response (CR or PR) in Subjects | 16 of 243 | 0 of 118 | 361 | NCT00075218 | Trial comparisons |
Nilotinib vs Control/Cross Over to Nilotinib: Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Central Radiology Review During Primary Analysis (Data Cut-off: June, 2008) | 1 of 165 | 0 of 83 | 248 | NCT00471328 | Trial comparisons |
| Sunitinib Double-Blind Treatment vs Placebo Double-Blind Treatment: Subjects With Pain Relief Response Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI) | 46 of 150 | 10 of 75 | 225 | NCT00075218 | Trial comparisons |
| Imatinib Mesylate 400 mg vs Imatinib Mesylate 600 mg: serious adverse events | 46 of 73 | 40 of 74 | 147 | NCT00237185 | Trial comparisons |
| Ripretinib vs Placebo: deaths from any cause | 26 of 85 | 26 of 43 | 128 | NCT03353753 | Trial comparisons |
| Ripretinib vs Placebo: serious adverse events | 26 of 85 | 19 of 43 | 128 | NCT03353753 | Trial comparisons |
| Ripretinib vs Sunitinib: Objective Response Rate (ORR) | 16 of 54 | 11 of 54 | 108 | NCT04633122 | Trial comparisons |
| Ripretinib vs Sunitinib: deaths from any cause | 13 of 54 | 15 of 54 | 108 | NCT04633122 | Trial comparisons |
| Ripretinib vs Sunitinib: Disease Control Rate (DCR) | 24 of 54 | 20 of 54 | 108 | NCT04633122 | Trial comparisons |
| Ripretinib vs Sunitinib: serious adverse events | 9 of 54 | 12 of 54 | 108 | NCT04633122 | Trial comparisons |
| Nilotinib 800 mg vs Imatinib 800 mg: serious adverse events | 12 of 48 | 10 of 46 | 94 | NCT00751036 | Trial comparisons |
| Imatinib vs Placebo: serious adverse events | 1 of 41 | 2 of 40 | 81 | NCT01151852 | Trial comparisons |
| All Participants Who Received Sunitinib vs Imatinib: serious adverse events | 11 of 43 | 5 of 25 | 68 | NCT00372567 | Trial comparisons |
| Sunitinib (Phase 3) vs Imatinib: Number of Participants With Objective Response of Complete Response or Partial Response | 5 of 31 | 2 of 26 | 57 | NCT00372567 | Trial comparisons |
| Cohort A vs Cohort B: Number of Participants With Physical Examination | 6 of 30 | 1 of 15 | 45 | NCT01874665 | Trial comparisons |
| Cohort A vs Cohort B: deaths from any cause | 4 of 30 | 2 of 15 | 45 | NCT01874665 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011719/comparisons